Transaction details
Christine Bellon, Chief Legal Officer at Beam Therapeutics (NASDAQ: BEAM), executed a sale of 5,956 common shares on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $24.58 apiece, producing gross proceeds of $146,398. The filing states the sale was automatic and intended to satisfy tax withholding obligations associated with restricted stock units as they vested.
Ownership after the sale and trading plan
Following the disposition, Bellon directly holds 109,711 shares of Beam Therapeutics. The filing notes the trades were carried out under a Rule 10b5-1 trading arrangement that Bellon adopted on May 19, 2023. The Form 4 indicates this was a prearranged sale under that plan rather than a discretionary, contemporaneous decision to sell.
Market context
Beam’s share price has experienced notable movement over the past year, rising nearly 59% in that period, while remaining down roughly 13% year-to-date. An InvestingPro analysis cited in the filing states the stock appears to trade below its Fair Value and highlights that the company carries more cash than debt on its balance sheet - one of 12 ProTips available to subscribers. The analysis and related Pro Research Report are identified as part of the suite of research available to InvestingPro users covering more than 1,400 U.S. equities.
Clinical developments and analyst responses
Beam Therapeutics has recently publicized clinical data that figures prominently in the company narrative. The Phase 1/2 BEACON trial results were published in The New England Journal of Medicine. That trial enrolled 31 patients with sickle cell disease and evaluated risto-cel.
Separately, Beam reported data from a clinical program addressing alpha-1 antitrypsin deficiency (AATD). The company identified a 60 mg dose as the pivotal dose for future development, a determination that has been incorporated into several analysts’ assessments.
Following these disclosures, a number of firms either reiterated or raised recommendations and price targets. Bernstein SocGen Group reiterated an Outperform rating with a $40.00 price target. Leerink Partners raised its price target from $42 to $47, citing the updated Phase 1/2 data. William Blair reiterated an Outperform rating, noting the high mean serum AAT levels observed in the trial. Clear Street maintained a Buy rating with a $37.00 price target and affirmed the identified dose as appropriate for pivotal development.
What this means in context
The insider sale reported here was described by the filing as an automatic action to cover taxes tied to RSU vesting and was completed under a previously established Rule 10b5-1 plan. At the same time, Beam’s clinical announcements and subsequent analyst activity are part of the public record and have informed the investment community’s view of the company’s development programs and valuation metrics cited by InvestingPro.